Best Practice & Research Clinical Rheumatology
Volume 21, Issue 5 , Pages 943-967, October 2007

The course of established rheumatoid arthritis

  • David L. Scott (Professor of Clinical Rheumatology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 207 848 5215; Fax: +44 207 848 5202.

Department of Rheumatology, Kings College London School of Medicine, Weston Education Centre, 10 Cutcombe Road, London SE5 9RS, UK

Rheumatoid arthritis (RA) varies over time in individual patients and there are marked differences between patients in its impact and progression. The course of RA is therefore unique to each individual patient and is affected by the overall pattern of disease; many patients have classical polyarticular disease but there is also a range of subtypes, such as fibromyalgic and polymyalgic disease. Some patients with RA enter a period of sustained remission; this varies between 10% and 36% of cases; its frequency is mainly influenced by the different approaches to studying RA patients over time, and does not represent a true difference in disease outcome. Most patients have persisting synovial inflammation and disease activity scores average between 3 and 4; there is some evidence that inflammation is less marked in late RA. Persisting synovitis results in increasing disability – this worsens by an average of 0.6% each year – and in joint damage, which increases by an average of 2% each year. Comorbidities and extra-articular features are commonplace: about one-third of patients, respectively, have associated cardiovascular disease, lung disease or extra-articular features, although severe extra-articular problems like vasculitis affect only about 10% of patients. Some aspects of the course of RA are influenced by genetic risks; currently these are only weak predictors but it is anticipated their value will increase with time.

Key words: clinical phenotype, disability, disease activity, disease outcome, genetic variation, remission, rheumatoid arthritis, X-ray damage

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(07)00062-9

doi:10.1016/j.berh.2007.05.006

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 5 , Pages 943-967, October 2007